



Board of Pharmacy Public Meeting Minutes

Pharmacy Board

Wednesday, December 18, 2024 at 9:00 AM EST to Wednesday, December 18, 2024 at 1:00 PM EST

Members Present: Karl Peicker -Chair(KP), David Rochefort(DP), Robert Theriault (RT), Purvi Patel(PP), Eric Lessard(EL)

Staff Present: Alex Fisher – Board Administrator, Cassandra Brown Esq. – Board Counsel

-Commissioner Rochefort left the meeting at 10:52AM.

I. Call To Order

II. Consent Agenda

- A. Approval of the Public Minutes from November 20, 2024
- B. NABP Update

-Approval of the Public Minutes from November 20, 2024 was removed from the consent agenda

- The following items from the NABP update were removed from the consent agenda

- Champions Challenge
- DEA CSOS
- DEA Telemed Extension
- 2025 NABP Member Meetings

Motion: Upon a motion by EL with a second by DR, the board voted to approve the consent agenda. Motion passes 5-0.

III. Approval of the Public Minutes from November 20, 2024

Motion: Upon a motion by BT with a second by EL, the board voted to approve the public minutes from November 20, 2024 as amended. Motion passes 3-0-2. DR and PP abstained.

IV. NABP Topics

A. Champions Challenge

Motion: Upon a motion by EL with a second by DR, the board voted to deputize Purvi Patel to participate in the Champions Challenge. Motion passes 5-0.

B. DEA CSOS

1. Commissioner Lessard discussed the Controlled Substance Ordering System that was launched on December 9th, 2024 by the DEA.

C. DEA Telemed Extension

1. Commissioner Lessard provided an update regarding the DEA Telemed Extension that extends telemedicine flexibilities regarding the prescribing of controlled substances through December 31, 2025.

D. 2025 NABP Member Meetings

1. Commissioner Lessard mentioned the NABP Annual Meeting in May and the NABP District 1+2 meeting in October to the Board to keep it on their radar if any board members would like to attend these meetings.

V. Administrative Rules and Legislative Topics

A. Ph 100 - Hearing 11:00AM

1. Kaitlyn Simoneau provided public comment related to her concern regarding the definition of clinic. Kaitlyn stated that she will be submitting comments from the inspectors related to Ph 100.

B. Ph 200

Motion: Upon a motion by EL with a second by BT, the board voted to approve the PH 200 final proposal. Motion passes 5-0.

C. Ph 300

VI. Public Comments

A. Illegal GLP-1 Compounding

Motion: Upon a motion by DR with a second by EL, the board voted to dismiss the public comment. Motion passes 5-0.

B. New Hampshire Hospital Association

1. Kathy Bizzaro provided public comment related to the FDA's October Guidance for Industry, entitled "Temporary Policies for Compounding Certain Parenteral Drug Products." This would allow flexibility for licensed pharmacies to compound certain products on a non-patient specific basis provided several requirements are met.
2. Attorney Brown stated that the Board has a couple of legal options that they can consider regarding this. The board can either have each facility do a petition for a waiver of rules or have the board draft a standing order.

VII. New Business

A. CE Audit and Renewal

1. Commissioner Lessard mentioned that there appears to be disconnect regarding the CE audit renewal process and the CE audit. He was not able to renew his license until he satisfied the audit, however these should both be handled separately. The Board Administrator will be following up on this process.

VIII. Non Public Session

Non-Public session conducted for the purpose of discussing investigations of alleged licensee misconduct and other confidential Board business. Such a non-public session is authorized by RSA 91-A:3, II (c) & (e), RSA 91-A:5, IV, *Lodge v. Knowlton*, (1978), and the Board's executive and deliberative privileges.

Motion: Upon a motion by BT with a second by PP, the board voted to go into a non public session at 11:20AM. Roll call vote passes 4-0.

IX. Seal the Minutes of the Non Public Session

Minutes of the non-public session are sealed to maintain the privacy of the items discussed in non-public session pursuant to RSA 91-A:3, II (c), on the grounds that public disclosure may adversely affect the reputation of a person other than a Board member or render the proposed action ineffective.

Motion: Upon a motion by EL with a second by KP, the board voted to seal the minutes of the non public session. Motion passes 4-0.

X. Standing Order related to NHHA Public Comment

Motion: Upon a motion by EL with a second by PP, the board voted to deputize Attorney Brown to draft the standing order related to the FDA guidance and have Commissioner Theriault review it and then send to Commissioner Peicker to sign. Motion passes 4-0.

XI. Adjournment

-The board adjourned at 12:19PM. The next meeting is scheduled for Wednesday January 15th at 9:00AM.